Investor Relations

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company’s lead product candidate is HEPLISAV, an investigational adult hepatitis B vaccine. For more information visit

Events & Presentations

All events & presentations »

E-Delivery of Stockholder Communications

Beneficial stockholders
Registered stockholders

Annual Report and Proxy

2014 Proxy Statement
2013 Form 10-K